Logo

Castle Biosciences, Inc.

CSTL

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test t… read more

Healthcare

Diagnostics & Research

7 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$28.00

Price

+4.52%

$1.21

Market Cap

$849.239m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

+6.3%

EBITDA Margin

-0.6%

Net Profit Margin

+9.4%

Free Cash Flow Margin

+6.3%

EBITDA Margin

-0.6%

Net Profit Margin

+9.4%

Free Cash Flow Margin
Revenue

$357.278m

+3.5%

1y CAGR

+38.3%

3y CAGR

+40.1%

5y CAGR
Earnings

-$19.415m

-167.1%

1y CAGR

-7.0%

3y CAGR

-33.9%

5y CAGR
EPS

-$0.66

-172.6%

1y CAGR

-8.8%

3y CAGR

-33.7%

5y CAGR
Book Value

$470.030m

$561.177m

Assets

$91.147m

Liabilities

$36.650m

Debt
Debt to Assets

6.5%

1.4x

Debt to EBITDA
Free Cash Flow

-$489k

-30.5%

1y CAGR

+106.2%

3y CAGR

+52.0%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases